HomeCompareAPTX vs EPRT

APTX vs EPRT: Dividend Comparison 2026

APTX yields 2083.33% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 APTX wins by $14544499705.92M in total portfolio value
10 years
APTX
APTX
● Live price
2083.33%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$14544499705.99M
Annual income
$13,289,647,770,778,488.00
Full APTX calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — APTX vs EPRT

📍 APTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAPTXEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, APTX + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
APTX pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

APTX
Annual income on $10K today (after 15% tax)
$177,083.33/yr
After 10yr DRIP, annual income (after tax)
$11,296,200,605,161,714.00/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, APTX beats the other by $11,296,200,605,150,800.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of APTX + EPRT for your $10,000?

APTX: 50%EPRT: 50%
100% EPRT50/50100% APTX
Portfolio after 10yr
$7272249853.03M
Annual income
$6,644,823,885,395,664.00/yr
Blended yield
91.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

APTX
Analyst Ratings
2
Buy
5
Hold
1
Sell
Consensus: Hold
Price Target
$1.00
+941.7% upside vs current
Range: $1.00 — $1.00
Altman Z
-14.5
Piotroski
1/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

APTX buys
0
EPRT buys
0
No recent congressional trades found for APTX or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAPTXEPRT
Forward yield2083.33%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$14544499705.99M$63.4K
Annual income after 10y$13,289,647,770,778,488.00$12,840.73
Total dividends collected$14455710543.57M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$1.00$35.50

Year-by-year: APTX vs EPRT ($10,000, DRIP)

YearAPTX PortfolioAPTX Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$219,033$208,333.33$11,205$505.18+$207.8KAPTX
2$4,499,033$4,264,667.71$12,672$682.46+$4.49MAPTX
3$86,681,257$81,867,291.39$14,490$930.48+$86.67MAPTX
4$1,566,868,240$1,474,119,294.47$16,786$1,282.69+$1566.85MAPTX
5$26,579,804,805$24,903,255,789.01$19,753$1,791.56+$26579.79MAPTX
6$423,253,588,633$394,813,197,491.25$23,677$2,541.64+$423253.56MAPTX
7$6,328,542,537,504$5,875,661,197,666.76$29,008$3,672.99+$6328542.51MAPTX
8$88,877,753,676,302$82,106,213,161,172.67$36,463$5,425.08+$88877753.64MAPTX
9$1,172,758,817,952,321$1,077,659,621,518,678.10$47,238$8,221.57+$1172758817.91MAPTX
10$14,544,499,705,987,470$13,289,647,770,778,488.00$63,385$12,840.73+$14544499705.92MAPTX

APTX vs EPRT: Complete Analysis 2026

APTXStock

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

Full APTX Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this APTX vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

APTX vs SCHDAPTX vs JEPIAPTX vs OAPTX vs KOAPTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.